Market Research Logo

Inhalable Drug Delivery - Medical Devices Pipeline Assessment, 2018

Inhalable Drug Delivery - Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, “Inhalable Drug Delivery - Medical Devices Pipeline Assessment, 2018 provides an overview of Inhalable Drug Delivery currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Inhalable Drug Delivery pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Inhalable Drug Delivery under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Inhalable Drug Delivery and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry.
Reasons to buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Inhalable Drug Delivery under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Inhalable Drug Delivery Overview
3 Products under Development
3.1 Inhalable Drug Delivery - Pipeline Products by Stage of Development
3.2 Inhalable Drug Delivery - Pipeline Products by Segment
3.3 Inhalable Drug Delivery - Pipeline Products by Territory
3.4 Inhalable Drug Delivery - Pipeline Products by Regulatory Path
3.5 Inhalable Drug Delivery - Pipeline Products by Estimated Approval Date
3.6 Inhalable Drug Delivery - Ongoing Clinical Trials
4 Inhalable Drug Delivery - Pipeline Products under Development by Companies
4.1 Inhalable Drug Delivery Companies - Pipeline Products by Stage of Development
4.2 Inhalable Drug Delivery - Pipeline Products by Stage of Development
5 Inhalable Drug Delivery Companies and Product Overview
5.1 Acorda Therapeutics Inc Company Overview
5.1.1 Acorda Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.2 Amphastar Pharmaceuticals Inc Company Overview
5.2.1 Amphastar Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview
5.3 Baxter International Inc Company Overview
5.3.1 Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview
5.4 Bellerophon Therapeutics Inc Company Overview
5.4.1 Bellerophon Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.5 Breath Therapeutics Holding BV Company Overview
5.5.1 Breath Therapeutics Holding BV Pipeline Products & Ongoing Clinical Trials Overview
5.6 Canigma A.L LTD Company Overview
5.6.1 Canigma A.L LTD Pipeline Products & Ongoing Clinical Trials Overview
5.7 Edixomed Ltd Company Overview
5.7.1 Edixomed Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.8 iDTx Systems, Inc. Company Overview
5.8.1 iDTx Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.9 Impel NeuroPharma Inc Company Overview
5.9.1 Impel NeuroPharma Inc Pipeline Products & Ongoing Clinical Trials Overview
5.10 Kanabo Research Ltd Company Overview
5.10.1 Kanabo Research Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.11 Medical Developments International Ltd Company Overview
5.11.1 Medical Developments International Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.12 Medspray BV Company Overview
5.12.1 Medspray BV Pipeline Products & Ongoing Clinical Trials Overview
5.13 NeuroproteXeon Inc Company Overview
5.13.1 NeuroproteXeon Inc Pipeline Products & Ongoing Clinical Trials Overview
5.14 Next Safety, Inc. Company Overview
5.14.1 Next Safety, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.15 Nobilis Therapeutics Inc Company Overview
5.15.1 Nobilis Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.16 Sandoz International GmbH Company Overview
5.16.1 Sandoz International GmbH Pipeline Products & Ongoing Clinical Trials Overview
5.17 SmartAir Medical Company Overview
5.17.1 SmartAir Medical Pipeline Products & Ongoing Clinical Trials Overview
5.18 Syqe Medical Company Overview
5.18.1 Syqe Medical Pipeline Products & Ongoing Clinical Trials Overview
5.19 Texas Tech University Health Sciences Center Company Overview
5.19.1 Texas Tech University Health Sciences Center Pipeline Products & Ongoing Clinical Trials Overview
5.20 University of Texas Health Science Center at Houston Company Overview
5.20.1 University of Texas Health Science Center at Houston Pipeline Products & Ongoing Clinical Trials Overview
5.21 Vectura Group Plc Company Overview
5.21.1 Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview
5.22 Vero Biotech LLC Company Overview
5.22.1 Vero Biotech LLC Pipeline Products & Ongoing Clinical Trials Overview
5.23 Windtree Therapeutics Inc Company Overview
5.23.1 Windtree Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
6 Inhalable Drug Delivery- Recent Developments
6.1 Jun 01, 2018: Vectura Group Appoints Anne Whitaker As Non-Executive Director
6.2 May 22, 2018: Windtree Receives $0.7 Million SBIR Grant in Continuing Support of the AEROSURF Phase 2b Clinical Trial Completion
6.3 May 21, 2018: Baxter Highlights Business Strategies and Innovation at 2018 Investor Conference
6.4 May 17, 2018: Catalent Completes $5.5 Million Phased Clinical Storage Expansion At Kansas City Campus
6.5 May 16, 2018: Bellerophon to Present Positive Results from Phase 2 Study of INOpulse for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease at the American Thoracic Society 114th International Conference
6.6 May 16, 2018: EyePoint Pharmaceuticals Announces Appointment of Leonard Blum as Executive Vice President and General Manager, U.S.
6.7 May 10, 2018: Bellerophon Provides Business Update and Reports First Quarter 2018 Financial Results
6.8 May 09, 2018: European Distribution Partnership between NeuroproteXeon and Linde
6.9 May 08, 2018: Bellerophon Reaches Agreement with FDA on Study Design of Phase 2b Trial of INOpulse for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease
6.10 May 08, 2018: Inhalation Sciences’ new CEO Lena Heffler: science, sales, win-win
6.11 May 08, 2018: EyePoint Pharmaceuticals Reports Fiscal Third Quarter 2018 Results
6.12 May 01, 2018: Catalent Reports Third Quarter Fiscal 2018 Results
6.13 Apr 26, 2018: Baxter Reports First-Quarter 2018 Results And Increases Financial Outlook For Full-Year 2018
6.14 Apr 26, 2018: Catalent Announces Organizational Restructuring To Support Customer Demand For Fast, Integrated Biologics Development
6.15 Apr 26, 2018: Consort Medical: Director Declaration
6.16 Apr 24, 2018: Medical Developments International Announces the Approval of Penthrox in Finland
6.17 Apr 24, 2018: Catalent To Invest $5 Million At Somerset Site To Create New Drug Development And Modified Release Center Of Excellence
6.18 Apr 20, 2018: Vectura Announces Senior Management Change
6.19 Apr 20, 2018: Vectura Group: Directorate Change - Chief Financial Officer
6.20 Apr 19, 2018: Inhalation Sciences Names Lena Heffler As CEO
6.21 Apr 12, 2018: Catalent Completes $5.5 Million Expansion at Philadelphia Facility
6.22 Apr 10, 2018: Penthrox is approved in Canada
6.23 Apr 05, 2018: Penthrox Approved In Germany
6.24 Apr 05, 2018: TRELEGY ELLIPTA Approved In Canada As The First Single Inhaler Triple Therapy For The Treatment Of Appropriate Patients With COPD
6.25 Mar 27, 2018: Penthrox Approved In Sweden, Norway, Poland And Croatia
6.26 Mar 23, 2018: Aradigm Reports Fourth Quarter 2017 And Full Year Financial Results
6.27 Mar 21, 2018: Vectura Group: 2017 Preliminary Results
6.28 Mar 21, 2018: Vectura Group: 2017 Preliminary Results - Performance in-line with expectations, with strong in-market growth from key inhaled products
6.29 Mar 15, 2018: Bellerophon Reports Fourth Quarter and Full-Year 2017 Financial Results
6.30 Mar 14, 2018: The Israeli Ministry of Health has Approved Kanabo Research's Medical Cannabis Vaporizer as a Medical Device
6.31 Feb 28, 2018: Catalent Completes $4.6 Million Expansion at Singapore Facility
6.32 Feb 23, 2018: Nobilis Therapeutics Presents Its PTSD Clinical Development Program To The US Congress
6.33 Feb 20, 2018: Catalent Announces Changes to its Board of Directors
6.34 Feb 19, 2018: Penthrox : First order received for Austria
6.35 Feb 19, 2018: Penthrox Approved in Estonia
6.36 Feb 09, 2018: Aradigm Announces Personnel Changes
6.37 Feb 07, 2018: Impel NeuroPharma Announces Positive Results of Phase 1 Clinical Trial of INP104 for Treatment of Acute Migraine Headache
6.38 Feb 07, 2018: pSivida Reports Second Quarter FY2018 Results; Continues to Achieve Milestones and Timelines
6.39 Feb 05, 2018: Catalent Reports Second Quarter Fiscal 2018 Financial Results
6.40 Feb 01, 2018: Medical Developments International: Penthrox approved in Slovakia
6.41 Feb 01, 2018: Baxter Reports 2017 Fourth-Quarter and Full-Year Results
6.42 Jan 29, 2018: Bellerophon Therapeutics Announces Enrollment Exceeds 100 Patients in Phase 3 INOvation-1 Study Evaluating INOpulse for Treatment of Pulmonary Arterial Hypertension
6.43 Jan 18, 2018: Inhalation Sciences announces new recruitment and reorganization
6.44 Jan 03, 2018: Bellerophon Announces First Patient Enrolled in Phase 2b Study Evaluating INOpulse for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
7 Appendix
7.1 Methodology
7.2 About GlobalData
7.3 Contact Us
7.4 Disclaimer
1.1 List of Tables
Table 1: Inhalable Drug Delivery - Pipeline Products by Stage of Development
Table 2: Inhalable Drug Delivery - Pipeline Products by Segment
Table 3: Inhalable Drug Delivery - Pipeline Products by Territory
Table 4: Inhalable Drug Delivery - Pipeline Products by Regulatory Path
Table 5: Inhalable Drug Delivery - Pipeline Products by Estimated Approval Date
Table 6: Inhalable Drug Delivery - Ongoing Clinical Trials
Table 7: Inhalable Drug Delivery Companies - Pipeline Products by Stage of Development
Table 8: Inhalable Drug Delivery - Pipeline Products by Stage of Development
Table 9: Acorda Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 10: Drug Delivery Device - Neonatal Respiratory Distress Syndrome (RDS) - Product Status
Table 11: Drug Delivery Device - Neonatal Respiratory Distress Syndrome (RDS) - Product Description
Table 12: Amphastar Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 13: Primatene Mist - New Version - Product Status
Table 14: Primatene Mist - New Version - Product Description
Table 15: Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 16: ProMaxx Microsphere - Product Status
Table 17: ProMaxx Microsphere - Product Description
Table 18: Bellerophon Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 19: INOpulse - Product Status
Table 20: INOpulse - Product Description
Table 21: INOpulse - PH-COPD - Product Status
Table 22: INOpulse - PH-COPD - Product Description
Table 23: INOpulse - PH-ILD - Product Status
Table 24: INOpulse - PH-ILD - Product Description
Table 25: Bellerophon Therapeutics Inc - Ongoing Clinical Trials Overview
Table 26: INOpulse - A Phase 3, Placebo Controlled, Double-blind, Randomized, Clinical Study to Determine Efficacy, Safety, and Tolerability of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo in Symptomatic Subjects with PAH (Part 1 and Part 2)
Table 27: INOpulse - A Phase IIb Study of INOpulse in the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD)
Table 28: INOpulse - An Open-label Long-term Safety Study of Inhaled Nitric Oxide (iNO) for PAH
Table 29: INOpulse - INOvation-2 Clinical Study of INOpulse Device
Table 30: INOpulse - PH-COPD - Phase IIb Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects in Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease (PH-COPD)
Table 31: INOpulse - PH-ILD - A Randomized, Double-blind, Placebo-controlled Clinical Study to Assess the Safety and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) in Subjects with Pulmonary Hypertension Associated with Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2)
Table 32: Breath Therapeutics Holding BV Pipeline Products & Ongoing Clinical Trials Overview
Table 33: Lung-Targeted BOS Device - Product Status
Table 34: Lung-Targeted BOS Device - Product Description
Table 35: Canigma A.L LTD Pipeline Products & Ongoing Clinical Trials Overview
Table 36: Vaporiser Device - Product Status
Table 37: Vaporiser Device - Product Description
Table 38: Edixomed Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 39: NOx System - Cystic Fibrosis - Product Status
Table 40: NOx System - Cystic Fibrosis - Product Description
Table 41: NOx System - VAP - Product Status
Table 42: NOx System - VAP - Product Description
Table 43: iDTx Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 44: GoPilot - Product Status
Table 45: GoPilot - Product Description
Table 46: Impel NeuroPharma Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 47: POD Device - Product Status
Table 48: POD Device - Product Description
Table 49: Kanabo Research Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 50: VapePod - Product Status
Table 51: VapePod - Product Description
Table 52: Medical Developments International Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 53: Penthrox Inhaler - Paediatric - Product Status
Table 54: Penthrox Inhaler - Paediatric - Product Description
Table 55: Medical Developments International Ltd - Ongoing Clinical Trials Overview
Table 56: Penthrox Inhaler - Paediatric - A Randomized, Double-blind, Multicenter, Placebo Controlled Study to Evaluate the Safety and Efficacy of Methoxyflurane (PENTHROX) for the Treatment of Acute Pain in Children and Adolescents from 6 to Less Than 18 Years of Age (Presenting to an Emergency Department with Minor Trauma)
Table 57: Medspray BV Pipeline Products & Ongoing Clinical Trials Overview
Table 58: Device 0075 - Product Status
Table 59: Device 0075 - Product Description
Table 60: Product 0070 - Product Status
Table 61: Product 0070 - Product Description
Table 62: Product 0077 - Product Status
Table 63: Product 0077 - Product Description
Table 64: NeuroproteXeon Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 65: Xenon Inhalation Device - Product Status
Table 66: Xenon Inhalation Device - Product Description
Table 67: NeuroproteXeon Inc - Ongoing Clinical Trials Overview
Table 68: Xenon Inhalation Device - XePOHCAS - Xenon by Inhalation for Post Out of Hospital Cardiac Arrest Syndrome
Table 69: Next Safety, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 70: Pulmonary Drug Delivery Device - Product Status
Table 71: Pulmonary Drug Delivery Device - Product Description
Table 72: Nobilis Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 73: Zephyrus - Product Status
Table 74: Zephyrus - Product Description
Table 75: Sandoz International GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 76: FreePath Drug Delivery System - Product Status
Table 77: FreePath Drug Delivery System - Product Description
Table 78: SmartAir Medical Pipeline Products & Ongoing Clinical Trials Overview
Table 79: SmartAir DDM - Product Status
Table 80: SmartAir DDM - Product Description
Table 81: Syqe Medical Pipeline Products & Ongoing Clinical Trials Overview
Table 82: Syqe Inhaler - Product Status
Table 83: Syqe Inhaler - Product Description
Table 84: Texas Tech University Health Sciences Center Pipeline Products & Ongoing Clinical Trials Overview
Table 85: Inhalable Nanoparticle System - Product Status
Table 86: Inhalable Nanoparticle System - Product Description
Table 87: University of Texas Health Science Center at Houston Pipeline Products & Ongoing Clinical Trials Overview
Table 88: Pedinap - Product Status
Table 89: Pedinap - Product Description
Table 90: Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 91: VR475 Combination Device - Product Status
Table 92: VR475 Combination Device - Product Description
Table 93: VR647 - Product Status
Table 94: VR647 - Product Description
Table 95: Vectura Group Plc - Ongoing Clinical Trials Overview
Table 96: VR647 - A Phase I Clinical Study of VR-647
Table 97: VR647 - A Phase I Clinical Study of VR-647 in Adult Asthma Subjects
Table 98: VR647 - A Single-dose, Open-label, Randomized, Incomplete Block Design Trial to Characterize the Pharmacokinetics of VR647 Inhalation Suspension Delivered by the VR647 Inhalation System and Single Doses of Budesonide Delivered by a Conventional Jet Nebulizer in Pediatric Subjects Aged 4 to 8 Years with Wheezing, Reactive Airway Disease or Mild Asthma
Table 99: VR647 - Phase II Pharmacokinetic Study of VR-647 in Children
Table 100: VR647 - Phase III Study of VR-647
Table 101: Vero Biotech LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 102: GeNOsyl Acute DS - Product Status
Table 103: GeNOsyl Acute DS - Product Description
Table 104: GeNOSYL Nitrosyl Delivery Platform - Ambulatory System - Product Status
Table 105: GeNOSYL Nitrosyl Delivery Platform - Ambulatory System - Product Description
Table 106: Windtree Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 107: Aerosol Drug Delivery Device - Acute Lung Injury - Product Status
Table 108: Aerosol Drug Delivery Device - Acute Lung Injury - Product Description
Table 109: AEROSURF - Product Status
Table 110: AEROSURF - Product Description
Table 111: Capillary Aerosol Generator (CAG) - Product Status
Table 112: Capillary Aerosol Generator (CAG) - Product Description
Table 113: Windtree Therapeutics Inc - Ongoing Clinical Trials Overview
Table 114: AEROSURF - A Multinational, Multicenter, Masked, Randomized, Controlled Study to Assess the Safety and Efficacy of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age with Respiratory Distress Syndrome
Table 119: Glossary
1.2 List of Figures
Figure 1: Inhalable Drug Delivery - Pipeline Products by Stage of Development
Figure 2: Inhalable Drug Delivery - Pipeline Products by Segment
Figure 3: Inhalable Drug Delivery - Pipeline Products by Territory
Figure 4: Inhalable Drug Delivery - Pipeline Products by Regulatory Path
Figure 5: Inhalable Drug Delivery - Pipeline Products by Estimated Approval Date
Figure 6: Inhalable Drug Delivery - Ongoing Clinical Trials

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report